Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026
Summit Therapeutics announced 10 ESMO 2026 presentations of ivonescimab data across biliary tract, endometrial, thymic, renal, and other cancers, led by a Phase III HARMONi-GI1 overall survival readout selected for the Presidential Symposium. Separately, Summit and ECOG-ACRIN initiated the Phase II/III EA2251 trial testing ivonescimab versus pembrolizumab or durvalumab combinations in first-line U.S. biliary tract cancer, with site activation expected in Q4 2026.
Key figures
- Drug Name
- ivonescimab (SMT112/AK112)
- Phase Of Trial
- Phase III
- Esmo presentations
- 10
- Phase3 studies total
- 17
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.